Monthly Archives

2 Articles

Posted by admin on

The Impact of Oncotarget Journal Remains Stable According to Research Gate

Oncotarget’s RG journal impact figures show that the journal’s impact remained relatively stable in 2015/2016 compared to 2014. The statistics show that the journal average citations frequency stood at 3.41 times, which is only 0.28 times less than 2014. This figure means that every article published in the journal was cited 3.41 timesby other people on average. The 2014 value of 3.69 was a significant improvement when compared with the year 2013 when the average stood at 2.85 times. The journal’s lowest figure, .019, was recorded in its first year of publication, 2010. A year later, that value increased to 1.69 and then 2.90 in the year 2012. These numbers show that more and more scientists and researchers are using the articles published in the journal in their work.

Oncotarget to Increase Its Weekly Issues to Two

On September 19, 2017, PR News reported that Oncotarget would be publishing two issues in a week. The issues will be made available in various high-profile indexes and archives. The report further added that the journal had assured its readers the continued availability of its scientific publications in PubMed, Biological Extracts, and EMBASE among others. The journal is planning to work with the National Library of Medicine to ensure it achieves its dream of submitting an issue to PubMed shortly after publishing it online.

For a long time, Oncotarget has worked with authoritative scientific indexes and archives to enhance the availability of various scientific results to researchers, medical practitioners, and the society at large. The decision to increase weekly publishes to two will boost the indexing processes. More scientific articles and their findings will be available online faster than before.

About Oncotarget

Oncotarget is a medical journal that was started in 2010 and discusses research about oncology. Mikhail Blagosklonny and Andrei V. Gudkov work as the editors-in-chief of the journal published by Impact Journals. The journal also covers topics related to cancer, endocrinology, pathology, age-linked ailments, physiology, and immunology. In as far as cancer is concerned, the journal looks at the treatment methods of the different types of cancer, the potential targets for treatment, and the various treatment requirements that can be used to enhance the lives of cancer patients.


Posted by admin on

Sahm Adrangi Chips in on the Current State of GNC

Soon after the publication of last week’s piece, former Wall Street bond trader, credit analyst, and credit portfolio manager reached out with the aim of discussing GNC Holdings. Over the weekend, the retired manager found time to speak and had a lot prepared based on previous articles written.

In response to the last thesis on GNC, the retired credit analyst shared the opinions of the argument wholly. He added that on several occasions, he has taken to the stores, conducted channel checks as he and his wife moved to Chapel Hill area. Sahm Adrangi acknowledges that there is a decent traffic trend in the region. However, he points out that there is a disconnect between the bears’ thesis and his experience in the stores. He adds that there is an undeniably big lag between now and when it shows in the numbers. Sahm Adrangi says that for a long time now, Wall Street has lacked the imagination to envision the turn. Wall Street still employs the ratios and financial models of the old GNC.

Another interesting thing that Sahm Adrangi said is that GNC is trading poorly because the bond folks are paying attention to equity as their measure. Additionally, the bond folks like the idea of having a big market capitalization cushion. The equity is used as the proverbial white smoke to signal that it’s clear to make trades. Additionally, the Titan offered key insight that was missed on the pieces before. He pointed out that had laid of15% of its staff on December 1st, 2016. For more info about us: click here.

Sahm Adrangi career began with an internship position at Merrill Lynch desk in New York. He worked at this institution for three years trading credit and bonds. Later, he moved to Longacre and took up a credit trading role. He would then move to Paulson&Co. At this company, his responsibility was in shorting mortgage bonds. At Bowery Investment Management he worked as a credit PM for three years. In June 2015, he quit Wall Street.

It was not until 2009 when Sahm Adrangi formed Kerrisdale Capital Management. Today, he is the chief investment officer. Under his leadership, Kerrisdale Capital Management has grown to manage over $150 million as of mid-2017.